Imagine a specialized 'biological eraser' that wipes away dead, infected skin without touching the healthy parts. Instead of using a painful scalpel to cut out bad tissue, this plant-based enzyme liquid dissolves the waste. It clears the way for the body to heal itself much faster and with less pain.
Diabetic Foot Ulcers (DFUs) often require surgical debridement which is painful and requires specialists. Current non-surgical options are too slow, leading to higher infection rates and avoidable amputations.
A plant-derived enzymatic debridement agent (EscharEx) and a scientifically robust Phase 2 clinical protocol approved by the FDA and EMA.
If you are a pharmaceutical company dealing with the slow recovery rates of chronic wounds — this project developed EscharEx, a plant-derived enzymatic agent that removes necrotic tissue without harming viable skin. This allows for faster wound progression and reduced complications.
If you are a clinic dealing with the impracticality of surgical sharp debridement in outpatient settings — this project developed a non-surgical alternative that is swift and safe. It reduces the need for highly trained surgical specialists for every dressing change.
If you are a medical device firm dealing with the high failure rate of non-surgical debridement options — this project developed a bioactive therapy based on proteolytic enzymes. It provides an optimal wound bed for healing, improving the likelihood of successful recovery.
Based on available project data, specific pricing or cost-per-unit information is not provided, though the project aims to reduce overall healthcare costs by preventing amputations.
The project leverages a shared active pharmaceutical ingredient with NexoBrid, which is already EMA and FDA-approved, suggesting an existing pathway for industrial production.
Based on available project data, the therapy is developed by MediWound Ltd. as EscharEx®, indicating proprietary ownership and trademarking.
The project is currently generating clinical and regulatory evidence, including the submission of a Phase 2 study protocol to the FDA and EMA for review.
The project runs from 2024-12-01 to 2026-11-30 to prepare the Investigational Medicinal Product Dossier (IMPD) and clinical evidence required for market approval.
The project is led by a single SME, MediWound Ltd. from Israel, with a 100% industry ratio. This lean structure indicates a fast-track commercialization approach, relying on the company's internal expertise and the existing regulatory success of their previous product, NexoBrid.
Contact MediWound Ltd. regarding EscharEx clinical trial partnerships.
Contact us to explore licensing opportunities for enzymatic wound care.
